BioTime, Inc. (NYSEMKT:BTX)

bshelton3 (< 20) Submitted: 2/8/2013 5:22:53 PM : Start Price: $4.28 BTX Score: -14.13

buy

Tarantula (< 20) Submitted: 12/20/2012 10:12:27 AM : Start Price: $3.45 BTX Score: +3.54

Like all early-stage biotechs, BioTime's success relies not on its ability to develop novel treatments, but to get them through clinical trial and regulatory testing. BTX isn't setup for that - so my assumption is that they demonstrate high potential with their adult-based stem cell lines, and sell the technology out. Still, be prepared for a loooooong wait.

yanngp (< 20) Submitted: 2/17/2012 6:46:26 PM : Start Price: $5.49 BTX Score: -47.39

Very long term investment

TMFBiologyFool (99.09) Submitted: 5/5/2011 6:24:34 PM : Start Price: $6.15 BTX Score: +57.05

http://www.fool.com/investing/general/2011/05/05/the-bearish-case-for-biotime.aspx

Brurobin (< 20) Submitted: 4/28/2011 3:34:05 PM : Start Price: $7.07 BTX Score: -64.66

Breakthrough technology.

psmitty (< 20) Submitted: 3/14/2011 11:17:10 AM : Start Price: $7.90 BTX Score: -77.15

Dr. West. CEO

dcooper101 (66.95) Submitted: 3/4/2011 9:23:27 AM : Start Price: $8.05 BTX Score: -74.28

This company has a market cap of less than $400 M and a pipeline of product candidates that, if successful, could easily generate sales in the hundreds of millions or even billions. The industry average P/S multiple for pharma & biotech is 3.31. If the company develops one successful $1B candidate and is bought out for half the average multiple, then you have at least a 3-bagger even after dilution.

rattlernum3 (< 20) Submitted: 10/10/2010 1:31:21 PM : Start Price: $5.47 BTX Score: -68.08

Regen medician is going to sci rocket if this stuff will by pass the big farma and fda money makers.
BTIM

ColourPurple (< 20) Submitted: 2/10/2010 7:24:04 PM : Start Price: $4.95 BTX Score: -73.49

Innovative and creative company that can change medicine as we know it

whatsupprahalad (< 20) Submitted: 10/20/2009 3:19:13 PM : Start Price: $5.10 BTX Score: -72.77

Biotime has Dr Michael West as its CEO
Biotime primary growth machine is going to be Stem cell related products and assays.

Stem cell industry has the following major issues.

1. Purity.
2. Scalability
3. Histocompatibility

Histocompatibility is basically the rejection issues that are faced when there is an organ transplant. Even at the stem cell level the body can identify foreign bodies(stem cells) and will try and destroy them. iPS (induced Pluripotent Stem cell) is the technology which overcomes this problem.

The patients skin cells have stem cells (that is why the skin can regenerate) BTIM has a process in place to convert skin stem cells into the generic "like" embryonic stem cell process and this process is vector (virus) free process and called iPS

2. Scalability issues has been dealt with ACTCellerate growth process of growing stem cells in a growth medium

3. Purity issues have been resolved by using shot gun cloning. ie the required stem cell is selected from the more than 140 different types of stem cells and the selected stem cell is then grown and since it is selected/purified before growth/cloning the cells are 100% of the required type.

Company is one step ahead of the industry and hence delay in recognition.. get in now and this is a long term play on the future of medicine (your own body can provide the medicine -skin graft which can cure all your ills.)

VERY VERY STRONG BUY!!! MULTI-BAGGER for sure!!

http://whatsup-stockideas.blogspot.com

=happy investing

Displacement (< 20) Submitted: 9/28/2009 4:58:21 PM : Start Price: $4.26 BTX Score: +60.58

Read Tasty's comment.